Dare Bioscience director granted 10K stock options
Dare Bioscience director William H. Rastetter received a grant of stock options for 10,000 shares of common stock.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Dare Bioscience director William H. Rastetter received a grant of stock options for 10,000 shares of common stock. The options have an exercise price of $2.03 per share and expire on June 11, 2036. They vest in full on the earlier of the first anniversary of the grant date or immediately before the company’s first annual shareholder meeting after the grant date, subject to his continued board service. The options also become fully exercisable upon a change in control of Dare Bioscience.
Insider Trade Summary
Grant/Award: 10,000 shares
Grant/Award
1 txn
Insider
RASTETTER WILLIAM H
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 10,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 10,000 contracts (Direct)
Footnotes (1)
- F1. This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer.
Key Figures
Stock options granted: 10,000 options
Exercise price: $2.03 per share
Expiration date: June 11, 2036
+1 more
4 metrics
Stock options granted
10,000 options
Grant to director on June 11, 2026
Exercise price
$2.03 per share
Stock option exercise price
Expiration date
June 11, 2036
Option term end
Total options following transaction
10,000 options
Director’s derivative holdings after grant
Key Terms
Stock Option (right to buy), exercise price, change in control, vest in full
4 terms
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
exercise price financial
"conversion_or_exercise_price": "2.0300""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
change in control financial
"will become exercisable in full upon a change in control of the issuer"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
vest in full financial
"This option will vest in full on the earlier of the first anniversary"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Dare Bioscience (DARE) disclose in this Form 4 for William H. Rastetter?
Dare Bioscience reported that director William H. Rastetter received a grant of stock options for 10,000 shares of common stock. The options were awarded as a compensation-related grant and are not an open-market purchase or sale of existing shares.
What are the key terms of William H. Rastetter’s 10,000 Dare Bioscience stock options?
The grant covers 10,000 stock options with an exercise price of $2.03 per share and an expiration date of June 11, 2036. These options give him the right, but not the obligation, to buy Dare Bioscience common shares at that fixed price.
How do William H. Rastetter’s Dare Bioscience options vest according to the Form 4?
The options will vest in full on the earlier of the first anniversary of the June 11, 2026 grant date or immediately before Dare Bioscience’s first annual shareholder meeting after that date. Vesting requires his continued service as a director until that vesting event.
What happens to William H. Rastetter’s options if Dare Bioscience experiences a change in control?
The Form 4 footnote states the options will become fully exercisable upon a change in control of Dare Bioscience. This means that if such a transaction occurs, all 10,000 options would immediately be exercisable regardless of the normal vesting schedule.
Did William H. Rastetter buy or sell Dare Bioscience common stock in this filing?
No open-market buys or sells of Dare Bioscience common stock were reported. The filing shows only a grant of derivative securities: 10,000 stock options, classified as an acquisition under code A, with no corresponding sale transactions disclosed.
How many Dare Bioscience derivative securities does William H. Rastetter hold after this transaction?
After the grant, William H. Rastetter is reported as holding 10,000 stock options directly. These options are exercisable into 10,000 shares of Dare Bioscience common stock, reflecting his entire derivative position shown in this particular Form 4.
AI-generated analysis. How Rhea-AI works. Not financial advice.
